Company intelligence / Profile preview

Insys Therapeutics

Chandler, Arizona, United Statesen.wikipedia.org ↗

Ownership: Private
Development stage: Commercial

Overview

The company's main product Subsys (sublingual fentanyl spray) was approved in 2012 for breakthrough pain in cancer patients. The company was involved in illegal marketing practices, bribing doctors to prescribe Subsys for off-label uses, which led to criminal convictions of executives and the company's bankruptcy in 2019.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculessynthetic cannabinoidsfentanyl-based medications
Industry: Biotech

Drug pipeline

1 asset

Buvaya

Unknown

Beyond the preview

Go deeper on Insys Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Insys Therapeutics.

Explore the full profile